Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Juvenile Myelomonocytic Leukemia
100%
Azacitidine
100%
Hematopoietic Stem Cell Transplantation
83%
3-cycle
66%
Partial Remission
50%
Leukemia
33%
Monotherapy
33%
Leukemia Patients
33%
Newly Diagnosed
33%
Patient-completed
33%
Genome-wide DNA Methylation
33%
Clinical Benefit
16%
DNA Methylation Profiling
16%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
16%
Pharmacokinetics
16%
Complete Remission
16%
Plasma Concentration
16%
Antileukemic Activity
16%
Curative Treatment
16%
Novel Therapies
16%
Once-daily
16%
Long-term Efficacy
16%
Progressive Disease
16%
6-cycles
16%
Platelet Transfusion
16%
Variant Allele Frequency
16%
Long-term Safety
16%
Methylation Signature
16%
Specific Index
16%
Transfusion-free
16%
Well Tolerated
16%
Patient numbers
16%
Concentration-time Profile
16%
Safety Activities
16%
Medicine and Dentistry
Juvenile Myelomonocytic Leukemia
100%
Azacitidine
100%
Hematopoietic Stem Cell Transplantation
83%
Leukemia
33%
DNA Methylation
33%
Monotherapy
33%
Methylation
16%
Allogeneic Hematopoietic Stem Cell Transplantation
16%
Gene Frequency
16%
Progressive Disease
16%
Pharmacokinetics
16%
Thrombocyte Transfusion
16%
Diseases
16%
Median Follow Up
16%
Pharmacology, Toxicology and Pharmaceutical Science
Juvenile Myelomonocytic Leukemia
100%
Azacitidine
100%
Remission
66%
Monotherapy
33%
Leukemia
33%
Diseases
33%
Pharmacokinetics
16%
Immunology and Microbiology
Hematopoietic Stem Cell Transplantation
100%
DNA Methylation
40%
Gene Frequency
20%
Allogeneic Hematopoietic Stem Cell Transplantation
20%
Methylation
20%
Pharmacokinetics
20%
Blood Level
20%
Platelet
20%